Deutsche Bank analyst Emmanuel Papadakis maintained a Hold rating on GlaxoSmithKline (GSK – Research Report) today and set a price target of ...

JPMorgan raised the firm’s price target on GSK (GSK) to 1,500 GBp from 1,440 GBp and keeps an Underweight rating on the shares.Maximize Your ...

Teva Pharmaceutical Industries Ltd. ADR-2.66% $19.77B ...

In this article, we are going to take a look at where GSK plc (NYSE:GSK) stands against the other stocks. The stock market extended its winning streak on Wednesday, closing firmer as investors ...

Walmart’s latest brand and logo update has left some social media users baffled. On Jan. 13, the company announced in a press release on its website that it was launching a “comprehensive ...

Roula Khalaf, Editor of the FT, selects her favourite stories in this weekly newsletter. GSK launched a rare £2bn share buyback and raised its growth targets on the back of strong sales of ...

It came as the boss of the London-listed firm cheered an ‘excellent’ performance in 2024. GSK has increased its long-term sales guidance amid hopes for a boost from new speciality medicines ...

Copyright © 2025 MarketWatch, Inc. All rights reserved.

GSK has reached an agreement that it says will resolve 93% of the outstanding lawsuits brought against the company claiming that its gastrointestinal drug Zantac caused cancer. The company has ...

GSK has claimed its second breakthrough designation from the FDA for antibody-drug conjugate GSK5764227, which it licensed from China's Hansoh Pharma in a $1.7 billion deal. The status has been ...